Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 17, 2026

New Fed Chair Kevin Warsh Wants to Blow Up the Playbook That's Kept Stocks Rising for 15 Years. Here's What Investors Should Do Now.

View original at nasdaq.com
New Fed Chair Kevin Warsh Wants to Blow Up the Playbook That's Kept Stocks Rising for 15 Years. Here's What Investors Should Do Now. Key Points New Fed chair Kevin Warsh wants to shrink the Fed's balance sheet…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Investors should reduce exposure to QE-dependent stocks, increase exposure to financials like Berkshire Hathaway, shift bonds to shorter durations, build cash, and maintain a long-term perspective.

    60% confidence
  • Stock Advisor has a total average return of 993% compared to 207% for the S&P 500.

    60% confidence
  • Tech stocks with sky-high earnings multiples could see their valuations reduced as higher discount rates are applied to their projected future earnings if the Fed reduces its balance sheet.

    60% confidence
  • Kevin Warsh wants to aggressively reduce the Fed's balance sheet and believes the Fed should use interest rates rather than its balance sheet as a policy tool.

    60% confidence
  • Warsh's desire for a smaller Fed balance sheet means that the Fed Put is somewhat deeper out of the money but remains present in the event of a real crisis.

    60% confidence
  • A shrinking Fed balance sheet won't be catastrophic; markets will adapt over time to any changes under Warsh's leadership.

    60% confidence
  • The Fed's balance sheet disproportionately helps those with financial assets.

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · benchmark return207 percent
S&P 500 Index Fund · price appreciation6 multiple_x
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com